Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations

HER2 signaling is activated in response to somatic HER2 mutations, which are often found in invasive lobular breast cancer (ILC) and are associated with poor prognosis. Tyrosine kinase inhibitors (TKIs) have demonstrated considerable antitumor activity in patients with HER2-mutated advanced breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Hao, Qu, Man, Zhang, Guozhi, Yuan, Long, Shi, Qiyun, Wang, Yinhuan, Yang, Ying, Zhang, Yi, Qi, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Precision Medicine Clinic: Molecular Tumor Board
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322140/
https://www.ncbi.nlm.nih.gov/pubmed/37120151
http://dx.doi.org/10.1093/oncolo/oyad122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322140/
https://www.ncbi.nlm.nih.gov/pubmed/37120151
http://dx.doi.org/10.1093/oncolo/oyad122

Ejemplares similares